Geron survives, for now, but the jury at J&J is still out on the future of imetelstat
Geron has survived another scrape with disaster, but it’s still operating under a dark cloud.
This morning the biotech announced that J&J’s review of the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
